BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial

In an exclusive conversation with BioPharma APAC, Stefan Scheidl, VP and Global Head of Ophthalmology Medical Affairs at Roche, delves into the g...

December 02, 2024 | Interview

Shanghai MicuRx Completes Phase III Trial of MRX-4, Advances Toward NDA Submission in China

Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced the successful completion of its Phase III clinical trial of MRX-4 for inject...

December 02, 2024 | News

Minghui Pharmaceutical Announces Positive Phase III Results for MH004 Ointment in Treating Atopic Dermatitis

Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced...

December 02, 2024 | News

Telix and Grand Pharma Dose First Patient in Phase III ZIRCON-CP Trial for ccRCC Imaging in China

Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and Grand Pharmaceutical Group Limited (00512.HK, Grand Pharma) announce th...

November 29, 2024 | News

Allink Biotherapeutics Secures $42 Million Series A Funding to Drive Global Expansion of Next-Gen ADC and Bispecific Antibody Therapies

Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation bispecific antibody and antibody-drug conjugate (ADC) therapeutic...

November 29, 2024 | News

South Korea’s S.BIOMEDICS Announces Promising Phase 1/2a Data for TED-A9 Cell Therapy in Parkinson’s Disease

-S.BIOMEDICS revealed promising one-year post-transplant data from their Phase 1/2a clinical trial of the TED-A9 cell therapy for Parkinson's disease....

November 27, 2024 | News

Merck and Abbisko Report Phase III Success for Pimicotinib in TGCT Treatment

Phase III MANEUVER study met primary endpoint, with an objective response rate at week 25 of 54.0% for pimicotinib versus 3.2% for placebo (p<0.0001) ...

November 27, 2024 | News

HanAll Biopharma, Daewoong Pharmaceutical, and NurrOn Complete Phase 1 Study of HL192 (ATH-399A) for Parkinson’s Disease

HL192 (ATH-399A) was well tolerated with no major safety issues in any of the 76 participants. No serious treatment related adverse events were reported...

November 26, 2024 | News

GC Biopharma and Novel Pharma Dose First US Patient in Pioneering Clinical Trial for Sanfilippo Syndrome Type A

GC Biopharma and Novel Pharma announced that the first patient in the US has been dosed in multinational clinical trial with 'GC1130A', an innovative new d...

November 26, 2024 | News

Akeso's Penpulimab and Anlotinib Combo Accepted by NMPA for First-Line Advanced Liver Cancer Treatment

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the National Medical Products Administration (NMPA) of China has accep...

November 25, 2024 | News

ArkBio Completes Phase 1 Enrollment for AK0610, Pioneering RSV Prevention for Vulnerable Infants

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced the successful enrollment and dosing of all participants in a Phase 1 clinical study of AK061...

November 25, 2024 | News

Sanofi Partners with A*STAR and NSC Singapore to Pioneer Innovations in Acne Treatment

Sanofi, the Agency for Science, Technology and Research (A*STAR), and the National Skin Centre Singapore (NSC) established a Memorandum of Understanding to...

November 22, 2024 | News

Roche's Vabysmo Shows Promising Results in Treating Polypoidal Choroidal Vasculopathy in Asian Patients

Roche shared encouraging 16-week interim data from its ongoing Phase 3b/4 SALWEEN trial, revealing significant advancements in vision improvement and...

November 22, 2024 | News

Merck and Abbisko Report Positive Phase III Results for Pimicotinib in TGCT Across Asia, Europe, and North America

Phase III MANEUVER study met primary endpoint, with an objective response rate at week 25 of 54.0% for pimicotinib versus 3.2% for placebo (p<0.0001) ...

November 21, 2024 | News

Stay Connected